However, in a phase I clinical trial, patients with various solid tumors had eight serious adverse events (bowel ischemia, pneumonitis, papilledema, uveitis and grade 3 hypotension), and further studies are required to evaluate the safety and toxicity of IL-15 in humans [256]. The gene discussed is IL15; the disease is optic papillitis.